Vivace Therapeutics is a clinical-stage, oncology-focused biotechnology company based in the San Francisco Bay Area, developing small-molecule cancer therapeutics that target the Hippo-YAP signaling pathway. Its lead candidate, VT3989, is in clinical trials for mesothelioma and other solid tumors. - View it on GitHub